Metabolik sendrom ile erektil disfonksiyon ilişkisi

Erektil disfonksiyon ED ile hipertansiyon, dislipidemi, glukoz intoleransı ve obezite gibi aterosklerotik risk faktörleri arasında kuvvetli bir ilişki vardır ve tümü metabolik sendromun MS bileşenleri olarak bilinir. Risk faktörlerinin sayısı ile ED prevalansı ve aynı zamanda MS ile ED arasındaki ilişki son yayınlarda gösterilmiştir.Klinik ve epidemiyolojik araştırmalar MS ve kardiovasküler hastalık arasındaki bağlantıyı kanıtlamıştır. Erektil disfonksiyon ve kardiyovasküler hastalıklar, endotelyal disfonksiyona neden olan, hipertansiyon, diyabet, dislipidemi, obezite ve sigara tüketimi gibi aynı risk faktörlerini paylaşırlar. Mevcut literatürler ED ile endotel disfonksiyon arasında güçlü bağlantı olduğuna dair kanıtlar içermektedir. . Erektil disfonksiyonun başlangıcı, sistemik vasküler hastalıkların en erken belirtilerinden biri olarak görülür ve subklinik kardiyovasküler hastalıklar için erken bir belirteç olarak kabul edilebilir. ED, diabeti olan erkeklerde daha sık görülür ve prevalansı yaş ve diabetin süresi ile artma eğilimindedir. Özellikle MS’u olan hastalarda multifaktöryel ED etyolojisi mevcut problemi çözme zorluğunu artırmaktadır. Bu hasta populasyonunda müdahele ihtiyacını belirlemede sistematik bir değerlendirme gereklidir

Anahtar Kelimeler:

Metabolik sendrom, erektil disfonksiyon, endotelyal disfonksiyon

Relationship between metabolic syndrome and erectile dysfunction

There is a strong association between erectile dysfunction ED and the atherosclerotic risk factors, such as hypertension ,dyslipidemia, glucose intolerance and obesity and they are well known as the components of metabolic syndrome. Relationship between the number of these risk factors and the prevalence of ED have been demonstrated by recent literature which underlines the link between metabolic syndrome and erectile dysfunction. It has also been proven the association between metabolic syndrome and cardiovascular disease by clinical and epidemiologic studies. Erectile dysfunction and cardiovascular disease share the same risk factors hypertension, diabetes, dyslipidemia, obesity, and smoking all of which may cause endothelial dysfunction. Existing literature offers strong evidence that endothelial dysfunction and erectile dysfunction are linked. The earliest signs of systemic vascular disease is the onset of erectile dysfunction and might be considered as an early marker for subclinical cardiovascular disease. Erectile dysfunction is more common in diabetic males and its prevalence tends to increase with age and duration of diabetes. The multifactorial etiology of ED, especially in patients with the metabolic syndrome, increases the difficulty of managing this problem. A systematic evaluation should be required in this patient population in order to determine the need of intervention

Keywords:

Metabolic syndrome, erectile dysfunction, endothelial dysfunction,

PDF

___

Arıkan E. Obezite ve sendrom. Türkiye Klinikleri Endokri- noloji 2005; 1: 18-22.
Demir M. Obezite ve endotel hücre sistemi. Türkiye Klinik- leri Endokrinoloji 2005; 1: 31-5.
Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-3.
Einhorn D, Reaven GM, Cobin RH. et al. American Colle- ge of Endocrinology position statement on the insulin resis- tance syndrome. Endocr Pract 2003; 9: 237–52.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Educati- on Program (NCEP) Expert Panel on detection, evaluati- on, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97.
Adams RJ, Appleton S, Wilson DH, et al. Population com- parison of two clinical approachesto the metabolic syndro- me: Implications of the new International Diabetes Federa- tion consensus deŞnition. Diabetes Care 2005; 28: 2777–9.
NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993, 270: 83–90.
Matfin G: New treatments for erectile dysfunction. Fertil Steril 2003, 80: 40–5.
Mulhall J, Teloken P, Barnas J. Vasculogenic erectile dysfunction is a predictor of abnormal stress echocardiog- raphy. J Sex Med 2009; 6: 820-5.
Bacon CG, Mittleman MA, Kawachi I, et al.: Sexual functi- on in men older than 50 years of age: results from the he- alth professionals follow-up study. Ann Intern Med 2003; 139: 161–8.
Guay AT, Spark RF, Bansal S, et al. American Association of Clinical Endocrinologists (AACE) medical guidelines for clinical practice for the evaluation and treatment of male se- xual dysfunction: a couple’s problem—2003 update. Endocr Pract 2003; 9: 77–95.
Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association confe- rence on scientific issues related to definition. Circulation 2004; 109: 433–8.
Guven S, Kuenzi J, Matfin G: Diabetes mellitus and the me- tabolic syndrome. In Pathophysiology. Edited by Porth CM. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p. 987–1015.
La Vignera S, Condorelli RA, Tumino S, et al. Original evaluation of endothelial dysfunction in men with erec- tile dysfunction and metabolic syndrome. Int J Impot Res. 2012; 24 : 150-4.
Ford ES, Giles WH, Dietz WH. Prevalence of The Metabo- lic Syndrome Among US Adults: Findings From The Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
Alexander CM, Landsmann PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes and prevalen- ce of coronary heart disease among NHANES III partici- pants age 50 years and older. Diabetes 2003; 52: 1210-4.
Ginsberg HN, Stahlenhoef AF. The Metabolic Syndrome: Targetting dyslipidemia to reduce coronary risk. J Cardio- vasc Risk 2003; 10: 121-28.
Onat A, Ceyhan K, Başar O, et al. Metabolic syndrome: ma- jor impact on coronary risk in a population with low cho- lesterol levels a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165: 285-92.
Özsahin AK, Gökçel A, Sezgin N et al. Prevalence of the metabolic syndrome in a Turkish adult population. Diabe- tes Nutr Metab 2004; 17: 230- 4.
Girman JC, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scan- dinavian Simvastatin Survival Study and Air Force/ Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex- CAPS). Am J Cardiol 2004; 93: 136-41.
Asman G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) Study: Prevalence of Hyperlipidemia in Persons with Hypertension and/or Diabetes Mellitus and the Relationship to Coronary Heart Disease. Am Heart J 1998; 116: 1713-24.
Jastrzebska M, Przybycien K, Chelstowski K, et al.Increased levels of factor VII, fibrinogen and activity of plazminogen activator inhibitor during postprandial tryglyceridemia in patients with ischemic heart disease confirmed by angiog- raphy. Nutr Metab Cardiovasc Dis 1999; 9: 33-40.
El-Sakka AI, Tayeb KA. Vascular impairment of erection in patients with diabetes and Peyronie’s disease: Is that an ac- cumulative? J Sex Med 2009; 6: 1736-42.
Matfin G, Jawa A, Fonseca VA. Erectile dysfunction: inter- relationship with the metabolic syndrome. Curr Diab Rep 2005; 5: 64-9.
Saigal CS: Obesity and erectile dysfunction: common prob- lems, common solution? JAMA 2004; 291: 3011–2.
Romeo JH, Seftel AD, Madhun ZT, Aron DC: Sexual func- tion in men with diabetes type 2: association with glycemic control. J Urol 2000; 163: 788–91.
McCulloch DK, Campbell IW, Wu FC, et al.: The prevalence of diabetic impotence. Diabetologia 1980; 18: 279–83.
Fedele D, Coscelli C, Santeusanio F, et al. Erectile dysfunc- tion in diabetic subjects in Italy. Gruppo Italiano Stu- dio DeŞcit Erettile nei Diabetici. Diabetes Care 1998; 21: 1973–7.
Fedele D, Coscelli C, Cucinotta D, et al. Diade Study Group. Incidence of erectile dysfunction in Italian men with diabe- tes. J Urol 2001; 166: 1368–71.
Fedele D. Therapy insight: Sexual and bladder dysfunction associated with diabetes mellitus. Nat Clin Pract Urol 2005; 2: 282–90.
Klein R, Klein BE, Lee KE, et al.: Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Dia- betes Care 1996; 19: 135–41.
Esposito K, Giugliano F, Di Palo C, et al.: Effect of lifestyle changes on erectile dysfunction in obese men: a randomi- zed controlled trial. JAMA 2004; 291: 2978– 84.
Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22: 36–52.
Richardson D, Vinik A. Etiology and treatment of erectile failure in diabetes mellitus. Curr Diab Rep 2002; 2: 501–9.
Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003; 89: 251–3.
Levine LA, Kloner RA: Importance of asking questions abo- ut erectile dysfunction. Am J Cardiol 2000; 86: 1210–3.
De Angelis L, Marfella MA, Siniscalchi M, et al. Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia 2001; 44: 1155–60.
Theuma P, Fonseca VA. Novel cardiovascular risk factors and macrovascular and microvascular complications of dia- betes. Curr Drug Targets 2003; 4: 477–86.
Billups KL, Kaiser DR, Kelly AS, et al. Relation of C-reactive protein and other cardiovascular risk factors to penile vas- cular disease in men with erectile dysfunction. Int J Impot Res 2003; 15: 231– 6.
Chan NN, Chan JC: Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002; 45: 1609– 16.
Nash DT: Insulin resistance, ADMA levels, and cardiovas- cular disease. JAMA 2002; 287: 1451– 2.
Masuda H, Tsujii T, Okuno T, et al. Accumulated endoge- nous NOS inhibitors, decreased NOS activity, and impai- red cavernosal relaxation with ischemia. Am J Physiol Re- gul Integr Comp Physiol 2002; 282: 1730– 8.
Wei M, Macera CA, Davis DR, et al. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994; 140: 930-7.
Saltzman EA, Guay AT, Jacobson J. Improvement in erecti- le function in men with organic erectile dysfunction by cor- rection of elevated cholesterol levels: a clinical observation. J Urol 2004; 172: 255– 8.
Fink HA, Mac DR, Rutks IR, et al. Sildenafil for male erecti- le dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002; 162: 1349– 60.
Corona G, Razzoli E, Forti G, Maggi M. The use of phosp- hodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008; 31: 799-808.
Brock GB, McMahon CG, Chen KK, et al. Efficacy and sa- fety of tadalafil for the treatment of erectile dysfunction: re- sults of integrated analyses. J Urol 2002; 168: 1332– 6.
Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodi- esterase type 5 inhibitor, in patients with erectile dysfunc- tion: the first at-home clinical trial. Int J Impot Res 2001; 13: 192– 9.
DeSouza C, Parulkar A, Lumpkin D, et al. Acute and pro- longed effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25: 1336– 9.
Katz SD, Balidemaj K, Homma S, et al. Acute type 5 phosp- hodiesterase inhibition with sildenafil enhances flowmedia- ted vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845– 51.
Halcox JP, Nour KR, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardi- al ischemia. J Am Coll Cardiol 2002; 40: 1232– 40.
Gazzaruso C, Giordanetti S, De Amici E, et al. Relations- hip between erectile dysfunction and silent myocardial isc- hemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004; 110: 22– 6.
Corona G, Mannuci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J And 2009; 32: 587- 98.
Montorsi P, Ravagnani PM, GalLi S, et al. Association bet- ween erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right pa- tient. Eur Urol 2006; 50: 721- 31.